AngioDynamics shares draw attention after a smaller-than-expected adjusted loss and stronger fiscal 2027 guidance.
Stock Earnings Results
July 14, 2026
Table of Contents
July 14, 2026
AngioDynamics, Inc. (NASDAQ: ANGO) reported fiscal fourth-quarter 2026 results above expectations, with revenue growth, a smaller-than-expected adjusted loss, strong Med Tech sales, positive adjusted EBITDA, and fiscal 2027 guidance pointing to continued growth.
AngioDynamics is a medical technology company focused on vascular health, blood flow restoration, cancer treatment technologies, and minimally invasive devices used by physicians in fast-growing healthcare markets.
The company reported an adjusted loss of $0.07 per share, better than estimates for a loss of $0.11, representing a 36.4% earnings surprise. Revenue came in at $86.61 million, above estimates of $80.49 million, with revenue growth of 8.0%.
Fourth-quarter net sales were $86.6 million, up 8.0% from the prior-year quarter on a pro forma basis.
Med Tech net sales increased 16.7% to $41.8 million, marking the company’s seventh consecutive quarter of double-digit Med Tech growth.
Med Device net sales increased 1.1% to $44.8 million.
Gross margin improved to 54.0%, up 130 basis points from the prior-year quarter, helped by favorable pricing and a revenue mix shift toward Med Tech.
AngioDynamics reported a GAAP net loss of $11.4 million, or $0.27 per share. Adjusted net loss was $2.8 million, or $0.07 per share.
Adjusted EBITDA was $3.3 million, compared with $3.4 million a year earlier.
Auryon sales increased 14.4% to $17.8 million, marking the platform’s 20th consecutive quarter of double-digit growth.
NanoKnife sales increased 64.5% to $11.8 million, driven by 47.0% growth in probes and 132.5% growth in capital sales.
Mechanical Thrombectomy sales were $11.1 million, down 1.1% year-over-year. AlphaVac sales increased 38.4%, while AngioVac declined 15.8% against a tough comparison.
AngioDynamics advanced several clinical and regulatory milestones during the year.
The company received FDA IDE approval for the APEX-Return study evaluating the AlphaReturn Blood Management System with AlphaVac F1885.
It also received FDA IDE approval for the PAVE clinical study evaluating AngioVac for right-sided infective endocarditis.
NanoKnife also gained momentum after Palmetto GBA finalized local Medicare coverage for qualifying patients in prostate and liver cancer, effective July 5, 2026.
After fiscal year-end, AngioDynamics received FDA IDE approval for the RELIEF study evaluating NanoKnife IRE for benign prostatic hyperplasia.
AngioDynamics expects fiscal 2027 net sales of $336 million to $341 million.
Med Tech net sales are expected to grow 12% to 15%, while Med Device net sales are expected to be flat.
Gross margin is expected to range from 54% to 55%.
Adjusted EBITDA is expected to range from $13 million to $16 million.
Adjusted EPS is expected to range from a loss of $0.29 to a loss of $0.24.
The company also expects tariff impact in fiscal 2027 to be broadly similar to fiscal 2026.
Investors are likely watching Med Tech growth, NanoKnife adoption, Auryon momentum, AlphaVac growth, reimbursement progress, clinical trial milestones, gross margin, adjusted EBITDA, cash generation, and fiscal 2027 guidance.
The quarter showed continued progress in the company’s shift toward higher-growth Med Tech platforms.
AngioDynamics delivered a stronger quarter as its Med Tech transformation continued.
Revenue beat expectations, adjusted loss was smaller than expected, gross margin improved, and the company remained adjusted EBITDA positive. NanoKnife growth was especially strong, supported by reimbursement progress and clinical data, while Auryon continued its long run of double-digit growth.
The key question is whether AngioDynamics can turn Med Tech momentum into stronger profitability as it enters fiscal 2027.
Platforms like LevelFields track earnings beats, layoffs, dividend increases, leadership changes, dividend updates, and stock reactions together, helping investors identify when healthcare stocks are moving on real operating progress or clinical catalysts.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE